Drug Profile

Tazemetostat - Ipsen

Alternative Names: E-7438; EPZ-6438; EZ-438; IPN-60200; Tazemetostat hydrobromide - Ipsen; Tazverik

Latest Information Update: 10 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Epizyme
Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
Class Amines; Antineoplastics; Benzamides; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chordoma; Sarcoma; Follicular lymphoma; Soft tissue sarcoma; Diffuse large B cell lymphoma; Mesothelioma; Rhabdoid tumour
New Molecular Entity Yes

Marketed Follicular lymphoma; Sarcoma
Registered Non-Hodgkin's lymphoma
Phase II CNS cancer; Diffuse large B cell lymphoma; Endometrial cancer; Histiocytosis; Lymphoma; Mesothelioma; Ovarian cancer; Prostate cancer; Solid tumours; Synovial sarcoma
Phase I/II Bladder cancer; Non-small cell lung cancer
No development reported Rhabdoid tumour
Discontinued Mantle-cell lymphoma

22 Oct 2025 pharmacodynamics data from a preclinical trial in Solid tumour presented at the International Conference on Molecular Targets and Cancer Therapeutics 2025 ( AACR-NCI-EORTC-2025)
26 Sep 2025 Epizyme completes the phase-II TRuST trial in Diffuse large B-cell lymphoma, Follicular lymphoma, Synovial sarcoma, Mesothelioma and Solid tumours in Australia, Belgium, France, Poland, Ukraine, United Kingdom, and USA (PO) (NCT02875548)
29 Aug 2025 Phase-II clinical trials in Sarcoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Japan (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com